<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03892512</url>
  </required_header>
  <id_info>
    <org_study_id>Beni-Suef</org_study_id>
    <nct_id>NCT03892512</nct_id>
  </id_info>
  <brief_title>Dexmedetomidine and Esmolol Early Post Operative Cognitive Dysfunction</brief_title>
  <official_title>The Effect of Dexmedetomidine and Esmolol on Early Post Operative Cognitive Dysfunction After Middle Ear Surgery Under Hypotensive Technique :Comparative , Randomized Double Blinded Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beni-Suef University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beni-Suef University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dexmedetomidine is a highly selective α2adrenoceptor agonist recently introduced to
      anesthesia that produces dose dependent sedation, anxiolysis, and analgesia (involving spinal
      and supraspinal sites) without respiratory depression.

      From a pharmacokinetic perspective,dexmedetomidine has a half life of nearly 2 hours,
      duration of action of nearly 4 hour, and thus, a side effect profile that is shorter in
      duration than clonidine.

      Esmolol is a cardioselective beta₁ receptor blocker with rapid onset, a very short duration
      of action (elimination half-life is approximately 9 minutes) , and no significant intrinsic
      sympathomimetic or membrane stabilising activity at therapeutic dosages
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be a randomized double blinded study and will be carried by the Department of
      Anaesthesia at Beni-Suef University Hospital after obtaining approval from local research and
      ethical committee. Written informed consent will be obtained from each patient before
      operation. Aiming to assess of the early cognitive dysfunction after controlled hypotensive
      anesthesia with either dexmedetomidine or esmolol during middle ear surgeries
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">April 2019</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>assess the early cognitive dysfunction after controlled hypotensive anesthesia</measure>
    <time_frame>MMS will performed at 1 hour, 6 and 24 hours postoperatively .The mximum score will be 30 points, a decrease of 2 or more will be considered as cognitive function decline. score less than 23 will be considered as cognitive impairmen</time_frame>
    <description>mini mental state examination (MMSE) will be used for evaluation of cognitive function Data will be expressed in mean ± SD and were compared using analysis of variance (ANOVA). The significance of non-parametric data was determined using chi-square test. For all comparisons P &lt; 0.05 was considered significant.,</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">58</enrollment>
  <condition>Cognitive Dysfunction</condition>
  <arm_group>
    <arm_group_label>dexmedetomedine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The Patients will receive hypotensive anesthesia via I .V infusion with dexmedetomidine (Percedex .Pfizer CO ) .</description>
  </arm_group>
  <arm_group>
    <arm_group_label>esmolol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive hypotensive anesthesia via I .V infusion with esmolol ( Esmolol Hydrochloride . Baxter CO ).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esmolol Hydrochloride</intervention_name>
    <description>Patients will receive hypotensive anesthesia via I .V infusion with esmolol ( Esmolol Hydrochloride )</description>
    <arm_group_label>esmolol</arm_group_label>
    <other_name>esmolol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>The Patients will receive hypotensive anesthesia via I .V infusion with dexmedetomidine (Percedex )</description>
    <arm_group_label>dexmedetomedine</arm_group_label>
    <other_name>precedex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients aging 20-50 years ASA physical status I-II . Males , females

        Exclusion Criteria:

          1. hypertensive patient

          2. Patients receiving sedatives as midazolam.

          3. Patients with ischemic heart diseases, heart block, congestive heart failure, valvular
             heart diseases.

          4. Patients with cerebrovascular diseases.

          5. Patients with impaired kidney function.

          6. Patients with history of chronic liver diseases.

          7. Patients with asthma, chronic obstructive lung diseases.

          8. Patients with diabetes mellitus, coagulation disorders, pregnancy.

          9. Patients with history of allergy to the drugs used in the study or patients with
             substance abuse .
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samaa ak Rashwan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assisstant proffesor of anesthesia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Samaa ak Rashwan, MD</last_name>
    <phone>020120159125</phone>
    <email>samakassemrashwan@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beni-Suef University Hospital</name>
      <address>
        <city>Banī Suwayf</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samaa Rashwan, MD</last_name>
      <phone>0201270159125</phone>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 23, 2019</study_first_submitted>
  <study_first_submitted_qc>March 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2019</study_first_posted>
  <last_update_submitted>March 26, 2019</last_update_submitted>
  <last_update_submitted_qc>March 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beni-Suef University</investigator_affiliation>
    <investigator_full_name>Samaa Rashwan</investigator_full_name>
    <investigator_title>Samaa Abou Alkassem Rashwan</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Esmolol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

